What should I do if Emerge Weight Loss medication arrives warm?

What should I do if Emerge Weight Loss medication arrives warm?

Do not use an injectable GLP-1 product that arrives warm or inadequately refrigerated until the dispensing pharmacy and clinician resolve its suitability. FDA recommends not using these products when they arrive warm or without adequate refrigeration; contact the pharmacy for advice and the supplier about replacement.

Emerge’s FAQ makes broader stability claims about warm packages, but those claims are not evidence that your specific shipment stayed within validated limits. Keep the package, label, delivery time, and photos, and describe the condition accurately. Do not apply an approved pen’s storage allowance to a compounded vial.

What details should you send the pharmacy?

Photograph the outer package, insulation, cooling materials, and dispensing label without posting personal details publicly. Note when it arrived and when it was opened. Ask the dispensing pharmacy to assess the actual formulation, labeled storage conditions, transit duration, and any available temperature evidence.

A melted ice pack alone cannot establish the full temperature history, and a cold vial now does not prove it was stored correctly earlier. Describe observations rather than estimating an unsupported maximum temperature. Follow the product’s labeled storage instructions while the pharmacy advises on handling; do not freeze a product as an attempted repair.

What if the answer is only “it should be fine”?

Ask for a response tied to your pharmacy, formulation, lot or prescription, and shipping conditions. General internet reassurance is not a shipment-specific assessment. If suitability cannot be established, ask Emerge and the dispensing pharmacy about replacement and tell the clinician if treatment may be interrupted.

We have not inspected your package, measured its temperature, or reviewed a pharmacy stability study for that lot. This page therefore cannot clear the medication for use. The FDA’s warning should remain visible when a provider’s general FAQ offers broader reassurance. Replacement eligibility and timing also need confirmation from the service handling your order.

Document the delivery while the evidence is available

Keep the outer package, insulation, cooling materials, medication container, and label. Record when it arrived and when it was opened, and take clear photos of the condition. Save tracking information showing delays or delivery attempts. These details help the pharmacy assess what happened to the actual shipment rather than answer a hypothetical storage question.

Contact the dispensing pharmacy through verified details on the label and notify the supplier about the delivery concern. Provide the order reference, medication name, and the condition observed. Ask for written instructions and the replacement process. Do not discard the evidence before the supplier explains what it needs to investigate.

Do not apply another product’s storage allowance

A manufacturer’s pen may have a specific labeled room-temperature allowance. That allowance does not automatically apply to a compounded vial with different preparation, packaging, or instructions. A customer story about using a warm package also cannot establish the suitability of yours. The FDA recommends not using injectable GLP-1 drugs that arrive warm or inadequately refrigerated.

Ask the clinician how to handle a possible interruption while the pharmacy and supplier resolve the shipment. Do not use extra medicine beforehand, change the schedule yourself, or assume that putting the product back in a refrigerator reverses a temperature problem. Keep the clinical question separate from the replacement or refund request, and obtain a clear response tied to the medication you actually received.

Resolve the difference between FDA advice and reassurance

Emerge’s FAQ contains broad statements about warm medication stability. FDA’s current advice recommends not using injectable GLP-1 products that arrive warm or without adequate refrigeration. A general provider statement should not be treated as evidence that a particular parcel stayed within validated limits. Give the pharmacy the label and delivery details, ask about replacement, and involve the clinician if there may be a treatment gap. Keep a written record of the response. This article cannot inspect the medication or determine its suitability from a photo, and refrigeration after delivery does not establish that an earlier shipping problem was harmless.